|
Aerie Pharma's combo eye
drug succeeds, shares soar
Send a link to a friend
[June 25, 2014]
(Reuters) - Drug developer
Aerie Pharmaceuticals Inc said its single-drop eye
treatment was shown to be superior to each of its two
components in a mid-stage trial, sending its shares up
by about 24 percent in premarket trading.
|
|
 The drug, Roclatan, combines Aerie's other experimental glaucoma
drug Rhopressa with the approved latanoprost.
Patients treated with the drug experienced a significant reduction
in fluid pressure inside the eye, compared with those treated with
either latanoprost or Rhopressa.
Glaucoma is a condition in which increased eye pressure could damage
the optic nerve and lead to blindness, if left untreated.
Aerie Pharma said it would immediately start preparing for
Roclatan's late-stage trial.
It is also preparing to start a late-stage trial for Rhopressa early
in the third quarter.
The company's shares closed at $21.03 on the Nasdaq on Tuesday.
(Reporting By Amrutha Penumudi; Editing by Don Sebastian)
[to top of second column] |
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
